Optimal management of papulopustular rosacea: Rationale for combination therapy

Journal of Drugs in Dermatology

Volumn 11, Issue 7, 2012, Pages 838-844

  Bhatia, Neal D ^a   Del Rosso, James Q ^b  

^a Private Practice   (United States)

^b VALLEY HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; DOXYCYCLINE; DOXYCYCLINE HYCLATE; METRONIDAZOLE; MINOCYCLINE; TETRACYCLINE;

ARTICLE; BLOOD VESSEL PERMEABILITY; DOUBLE BLIND PROCEDURE; HUMAN; INFLAMMATION; INNATE IMMUNITY; NEUTROPHIL CHEMOTAXIS; PAPULOPUSTULAR ROSACEA; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROSACEA; SIGNAL TRANSDUCTION; STRATUM CORNEUM;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS; DERMATOLOGIC AGENTS; DICARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; DRUG THERAPY, COMBINATION; HUMANS; INFLAMMATION; METRONIDAZOLE; ROSACEA;

EID: 84866184098     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Wilkin J, Dahl M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the Classification and Staging of Rosacea. J Am Acad Dermatol. 2002;46(4):584-587.
2. Wise RD. Submicrobial doxycycline and rosacea. Compr Ther. 2007;33(2):78-81.
3. Baldwin HE. Oral therapy for rosacea. J Drugs Dermatol. 2006;5(1):16-21.
4. Wilkin J, Dahl M, Detmar M, et al; National Rosacea Society Expert Committee. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50(6):907-912.
5. Jansen T, Plewig G. Rosacea: classification and treatment. J R Soc Med. 1997;90(3):144-150.
6. Bikowski JB. Can subantimicrobial doxycycline really help without traditional side effects or resistance risks? What you should know about subantimicrobial dose doxycycline? Pract Dermatol. 2005;38-43.
7. Rosen T. Antibiotic resistance: an editorial review with recommendations. J Drugs Dermatol. 2011;10(7):724-733.
8. Del Rosso JQ, Leyden JJ. Status report on antibiotic resistance: implications for the dermatologist. Dermatol Clin. 2007;25(2):127-132.
9. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7(6):573-576.
10. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline , USP capsules) administered once daily for treatment of rosacea. J Am Acad Dematol. 2007;56(5):791-802.
11. Del Rosso JQ. A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effects of the tetracyclines. Cutis. 2004;74(2):118-122.
12. Webster GF. An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads). Cutis. 2010;86(5 suppl):7-15.
13. Del Rosso JQ. Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as addon therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial. Cutis. 2010;86(5 suppl):16-25.
14. Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6(6):641-645.
15. Del Rosso JQ, Bruce S, Jarratt M, Menter A, Staedtler G. Efficacy of topical azelaic acid (AzA) gel 15% plus oral doxycycline 40 mg versus metronidazole gel 1% plus oral doxycycline 40 mg in mild-to-moderate papulopustular rosacea. J Drugs Dermatol. 2010;9(6):607-613.
16. Del Rosso JQ, Baldwin H, Webster G; American Acne & Rosacea Society. American Acne & Rosacea Society rosacea medical management guidelines. J Drugs Dermatol. 2008;7(6):531-533.
17. Buechner SA. Rosacea: an update. Dermatology. 2005;210(2):100-108.
18. Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci. 2009;55(2):77-81.
19. Fleischer AB Jr. Inflammation in rosacea and acne: Implications for patient care. J Drugs Dermatol. 2011;10(6):614-620.
20. Dirschka T, Tronner H, Fölster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol. 2004;150(6):1136-1141.
21. Miyachi Y. Potential antioxidant mechanism of action for metronidazole: implications for rosacea management. Adv Ther. 2001;18(6):237-243.
22. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975-980.
23. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998:12(2);12-26.
24. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54(2):258-265.
25. Ryan ME, Usman A, Ramamurthy NS, Golub LM, Greenwald RA. Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity. Curr Med Chem. 2001;8(3):305-316.
26. Beaufort N, Plaza K, Utzschneider D, et al. Interdependence of kallikrein-related peptidases in proteolytic networks. Biol Chem. 2010;391(5):581-587.
27. Draelos ZD. Assessment of skin barrier function in rosacea patients with a novel 1% metronidazole gel. J Drugs Dermatol. 2005;4(5):557-562.
28. Draelos ZD. The rationale for advancing the formulation of azelaic acid vehicles. Cutis. 2006;7(2 suppl):7-11.
29. Akamatsu H, Komura J, Asada Y, Miyachi Y, Niwa Y. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res. 1991;283(3):162-166.
30. Jones D. Reactive oxygen species and rosacea. Cutis. 2004;74(3 suppl):17-20, 32-34.
31. Ertl GA, Levine N, Kligman AM. A comparison of the efficacy of topical tretinoin and low-dose oral isotretinoin in rosacea. Arch Dermatol. 1994;130(3):319-324.
32. Sanchez J, Somolinos AL, Almodóvar PI, Webster G, Bradshaw M, Powala C. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. J Am Acad Dermatol. 2005;53(5):791-797.
33. Thiboutot DM, Fleischer AB, Del Rosso JQ, Rich P. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy. J Drugs Dermatol. 2009;8(7):639-648.
34. Bhatia N. Case studies in rosacea: A 55-year-old man with centrofacial flushing and textural changes affecting his nose CME. Medscape CME released September 21, 2011, valid for credit through Sept. 21, 2012.
35. Baldwin HE. Systemic therapy for rosacea. Skin Therapy Lett. 2007;12(2):1-5, 9.
36. Blount BW, Pelletier AL. Rosacea: a common, yet commonly overlooked, condition. Am Fam Physician. 2002;66(3):435-440.